Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

Learn more about:
Related Clinical Trial
Deep Learning in Retinoblastoma Detection and Monitoring. Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma RB Liquid Biopsy Biorepository Topotecan and Melphalan for Retinoblastoma Effect of Anesthetic Drugs on Neurocognitive Function in Children With Retinoblastoma Requiring Multiple Anesthetic Exposure – Preliminary Study Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma. Autonomic Reflexes During Intra-arterial Chemotherapy for Retinoblastoma Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study Topotecan Episcleral Plaque for Treatment of Retinoblastoma G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment PCI Imaging System in Pediatric Ophthalmology Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients Conservative Treatments of Retinoblastoma Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma Photoscreening for Retinoblastoma RCT of Ballon Technique VS Selective Ophthalmic Artery Infusion For the Retinoblastoma Patients Studying Health Outcomes After Treatment in Patients With Retinoblastoma Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma Intra-arterial Chemotherapy for Retinoblastoma Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma Phase I Trial of Periocular Topotecan in Retinoblastoma Episcleral Topotecan for Treatment of Group D Retinoblastoma Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma? CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma Chemotherapy in Treating Patients With Retinoblastoma New Strategies to Detect Cancers in Carriers of Mutations in RB1 Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma Carboplatin Plus Vincristine in Treating Children With Retinoblastoma Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma Quality of Life in Children Cured of Retinoblastoma Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) Cardio-respiratory Events During Ophthalmic Artery Chemotherapy for Retinoblastoma Under a Deep Anesthesia Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma SPT Screening in Irradiated Hereditary Retinoblastoma Survivors Attention to Retinoblastoma Diagnosed in the Trauma Setting Carboplatin Periocular Injection for Retinoblastoma Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala Research on the Environment and Children’s Health: Retinoblastoma Intravitreal Injections of Melphalan for Retinoblastoma Efficacy Study of Lucentis in the Treatment of Retinoblastoma Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life Retinoblastoma Biomarker Study Cancer Biology of Retinoblastoma Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma Intra-arterial Chemotherapy for Children With Retinoblastoma Molecular Analysis of Retinoblastoma

Brief Title

Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

Official Title

Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated

Brief Summary

      Postoperative Treatment of Unilateral Retinoblastoma After Primary Enucleation according to
      histopathological risk factors of the International Retinoblastoma Staging Working Group.

Detailed Description

      Post operative chemotherapy +/- radiotherapy according to histopathological risk factors of
      the International Retinoblastoma Staging Working Group.

        -  Low risk group :

             -  No optic nerve involvement.

             -  Intra and prelaminar involvement

             -  No choroidal involvement.

             -  Minimal superficial choroidal involvement .

        -  Intermediate risk group, 2 sub groups :

             -  Sub group 1 :

                  -  Retrolaminar involvement without Invasion of surgical margin associated or not
                     to massive choroidal involvement

                  -  Anterior segment involvement.

                  -  Intrascleral involvement.

             -  Sub Group 2 :

                  -  Isolated massive choroidal involvement.

        -  High risk group :

             -  Invasion of the surgical margin of the optic nerve

             -  and/or microscopic extrascleral involvement

             -  Optic nerve meningeal sheat involvement .

Study Phase

Phase 2

Study Type


Primary Outcome

Rate of extra ocular relapses

Secondary Outcome

 Evaluate long term and acute toxicities of adjuvant chemotherapy and orbital irradiation if necessary.





Study Arms / Comparison Groups

 Low risk group


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

March 2010

Completion Date

September 2029

Primary Completion Date

March 2029

Eligibility Criteria

        Inclusion Criteria:

          1. Written informed consent - a signed informed consent and/or assent (as age
             appropriate) will be obtained according to institutional guidelines;

          2. Male or female ≥2 months and <10 years of age at the time of signing the informed
             consent form;

          3. Diagnosis of non familial extensive unilateral retinoblastoma treated by primary

          4. In case of post operative chemotherapy, patients must have adequate organ function:

               -  Adequate hematopoietic function Neutrophils>1.0x109/l, Platelets >100 x 109/l.

               -  Adequate hepatic function: grade II NCI CTC

               -  Adequate renal function: serum creatinemia <1.5 x ULN for age with normal
                  creatinine clearance estimated by SCHWARTZ formula

               -  Audiometry < Grade II de Brock.

               -  Echocardiography normal in case of high dose cyclophosphamide chemotherapy (3

          5. Patients affiliated to a Social Security Regimen or beneficiary of the same

          6. No chemotherapy or radiotherapy prior to administration of the first dose of study
             treatment for retinoblastoma or other tumor types

          7. Without medical cons-indication to study drugs.

        Exclusion Criteria:

          -  Bilateral and/or familial or trilateral retinoblastoma.

          -  Unilateral retinoblastoma with indication of primary chemotherapy before enucleation:

               -  One or several surgical risk factors

               -  Buphthalmia Exophthalmia.

               -  Peri ocular inflammatory signs.

               -  Extraocular extension :

               -  Radiological retrolaminar extension (more than 3 mm behind the lamina cribrosa)
                  and or meningeal sheat optic nerve extension.

               -  Extrascleral extension

               -  Lymp nodes extension

          -  Unilateral retinoblastoma with possibility of conservative treatment:

          -  Metastatic extension at diagnosis

          -  One inclusion criteria non observed

          -  Uncontrolled medical conditions, psychological, familial, sociological, or
             geographical conditions that do not permit compliance with the protocol




2 Months - 10 Years

Accepts Healthy Volunteers



, , [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID

IC 2009-04 RB SFCE 09

Responsible Party


Study Sponsor

Institut Curie

Study Sponsor

, , 

Verification Date

August 2020